{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:51:12Z","timestamp":1778201472491,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Leo Pharma Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s13555-024-01312-y","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:26:15Z","timestamp":1732778775000},"page":"75-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Italian Expert Opinion on Chronic Hand Eczema: from Guidelines to Clinical Practice"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-8141","authenticated-orcid":false,"given":"Luca","family":"Stingeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Belloni","family":"Fortina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiacomo Calzavara","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0536.2009.01669.x","volume":"62","author":"JP Thyssen","year":"2010","unstructured":"Thyssen JP, Johansen JD, Linneberg A, Menn\u00e9 T. The epidemiology of hand eczema in the general population\u2013prevalence and main findings. Contact Dermatitis. 2010;62:75\u201387.","journal-title":"Contact Dermatitis"},{"key":"1312_CR2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.0022-202X.2004.22406.x","volume":"122","author":"B Meding","year":"2004","unstructured":"Meding B, J\u00e4rvholm B. Incidence of hand eczema-a population-based retrospective study. J Invest Dermatol. 2004;122:873\u20137.","journal-title":"J Invest Dermatol"},{"key":"1312_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjd.13220","volume":"172","author":"L Scalone","year":"2015","unstructured":"Scalone L, Cortesi PA, Mantovani LG, Belisari A, Ayala F, Fortina AB, et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. Br J Dermatol. 2015;172:187\u201395.","journal-title":"Br J Dermatol"},{"key":"1312_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjd.15660","volume":"178","author":"S Cazzaniga","year":"2018","unstructured":"Cazzaniga S, Apfelbacher C, Diepgen T, Ofenloch RF, Weisshaar E, Molin S, et al. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. Br J Dermatol. 2018;178:229\u201337.","journal-title":"Br J Dermatol"},{"key":"1312_CR5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/DER.0000000000000598","volume":"31","author":"S Capucci","year":"2020","unstructured":"Capucci S, Hahn-Pedersen J, Vilsb\u00f8ll A, Kragh N. Impact of atopic dermatitis and chronic hand eczema on quality of life compared with other chronic diseases. Dermatitis. 2020;31:178\u201384.","journal-title":"Dermatitis"},{"key":"1312_CR6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86:357\u201378.","journal-title":"Contact Dermatitis"},{"key":"1312_CR7","first-page":"1054","volume":"21","author":"A Bauer","year":"2023","unstructured":"Bauer A, Brans R, Brehler R, B\u00fcttner M, Dickel H, Elsner P, et al. S2k guideline diagnosis, prevention, and therapy of hand eczema. J Dtsch Dermatol Ges. 2023;21:1054\u201374.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1312_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00890-z","author":"E Weisshaar","year":"2024","unstructured":"Weisshaar E. Chronic hand eczema. Am J Clin Dermatol. 2024. https:\/\/doi.org\/10.1007\/s40257-024-00890-z.","journal-title":"Am J Clin Dermatol"},{"key":"1312_CR9","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/jdv.19329","volume":"37","author":"AK Janstrup","year":"2023","unstructured":"Janstrup AK, N\u00f8rreslet LB, Toft-Hansen JM, Ofenloch R, Agner T, Y\u00fcksel YT. Assessment of hand eczema severity by patients using the hand eczema severity index ( HECSI ). Acad Dermatol Venereol. 2023;37:2349\u201354.","journal-title":"Acad Dermatol Venereol"},{"key":"1312_CR10","doi-asserted-by":"publisher","unstructured":"Y\u00fcksel YT, Thoning H, Larsen LS, Lehmann L, Arbuckle R, Grant L, et al. Evaluation of validity, reliability and ability to detect change for the Hand Eczema Severity Index (HECSI) and evaluation of HECSI-75 and HECSI-90 as within-patient responder definitions. Contact Dermatitis [Internet]. [cited 2024 Nov 6];n\/a. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/cod.14699","DOI":"10.1111\/cod.14699"},{"key":"1312_CR11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GBE, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808\u201317.","journal-title":"Br J Dermatol"},{"key":"1312_CR12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2005.11.1053","volume":"54","author":"JF Fowler","year":"2006","unstructured":"Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, et al. Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol. 2006;54:448\u201357.","journal-title":"J Am Acad Dermatol"},{"key":"1312_CR13","first-page":"562","volume":"156","author":"S Maden","year":"2021","unstructured":"Maden S, Ozbagcivan O, Onur Aysevener BE, Aktan S. Quality of life, anxiety, depression, social anxiety and avoidance in patients with chronic hand eczema. Ital J Dermatol Venerol. 2021;156:562\u20139.","journal-title":"Ital J Dermatol Venerol"},{"key":"1312_CR14","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.3390\/jcm12175741","volume":"12","author":"A Zalewski","year":"2023","unstructured":"Zalewski A, Krajewski PK, Szepietowski JC. Psychosocial consequences of hand eczema\u2014a prospective cross-sectional study. JCM. 2023;12:5741.","journal-title":"JCM"},{"key":"1312_CR15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0536.2012.02062.x","volume":"67","author":"D Boehm","year":"2012","unstructured":"Boehm D, Schmid-Ott G, Finkeldey F, John SM, Dwinger C, Werfel T, et al. Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema. Contact Dermatitis. 2012;67:184\u201392.","journal-title":"Contact Dermatitis"},{"key":"1312_CR16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/cod.12366","volume":"72","author":"A Kouris","year":"2015","unstructured":"Kouris A, Armyra K, Christodoulou C, Katoulis A, Potouridou I, Tsatovidou R, et al. Quality of life, anxiety, depression and obsessive-compulsive tendencies in patients with chronic hand eczema. Contact Dermatitis. 2015;72:367\u201370.","journal-title":"Contact Dermatitis"},{"key":"1312_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2133.2009.09099.x","volume":"161","author":"C Moberg","year":"2009","unstructured":"Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161:397\u2013403.","journal-title":"Br J Dermatol"},{"key":"1312_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/cod.14407","volume":"89","author":"AS Quaade","year":"2023","unstructured":"Quaade AS, Alinaghi F, Dietz JB, Erichsen CY, Johansen JD. Chronic hand eczema: a prevalent disease in the general population associated with reduced quality of life and poor overall health measures. Contact Dermatitis. 2023;89:453\u201363.","journal-title":"Contact Dermatitis"},{"key":"1312_CR19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag"},{"key":"1312_CR20","doi-asserted-by":"publisher","unstructured":"Christoffers WA, Coenraads P-J, Svensson \u00c5, Diepgen TL, Dickinson-Blok JL, Xia J, et al. Interventions for hand eczema. Cochrane Skin Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2019 [cited 2024 Feb 11];2019. Available from: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1002\/14651858.CD004055.pub2","DOI":"10.1002\/14651858.CD004055.pub2"},{"key":"1312_CR21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2230.2009.03649.x","volume":"34","author":"J English","year":"2009","unstructured":"English J, Aldridge R, Gawkrodger DJ, Kownacki S, Statham B, White JML, et al. Consensus statement on the management of chronic hand eczema. Clin Exp Dermatol. 2009;34:761\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"1312_CR22","first-page":"77","volume":"13","author":"TL Diepgen","year":"2015","unstructured":"Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema\u2013short version. J Dtsch Dermatol Ges. 2015;13:77\u201385.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1312_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ad.2019.04.005","volume":"111","author":"JF Silvestre Salvador","year":"2020","unstructured":"Silvestre Salvador JF, Heras Mendaza F, Hervella Garc\u00e9s M, Palacios-Mart\u00ednez D, S\u00e1nchez Camacho R, Senan Sanz R, et al. Guidelines for the diagnosis, treatment, and prevention of hand eczema. Actas Dermosifiliogr (Engl Ed). 2020;111:26\u201340.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"1312_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5021\/ad.2021.33.4.351","volume":"33","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Bang CH, Kim HO, Lee DH, Ko JY, Park EJ, et al. 2020 Korean consensus guidelines for diagnosis and treatment of chronic hand eczema. Ann Dermatol. 2021;33:351\u201360.","journal-title":"Ann Dermatol"},{"key":"1312_CR25","unstructured":"Ishikawa K, Loftus JH. Introduction to quality control. 3rd ed. Tokyo: 3A Corporation; 1990."},{"key":"1312_CR26","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.3390\/jcm12103545","volume":"12","author":"MC Fargnoli","year":"2023","unstructured":"Fargnoli MC, Bardazzi F, Bianchi L, Dapavo P, Fabbrocini G, Gisondi P, et al. Brodalumab for the treatment of moderate-to-severe psoriasis: an expert delphi consensus statement. J Clin Med. 2023;12:3545.","journal-title":"J Clin Med"},{"key":"1312_CR27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, Plohberger U, Thoning H, Arbuckle R, et al. Validation of the investigator global assessment of chronic hand eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316:110.","journal-title":"Arch Dermatol Res"},{"key":"1312_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1312_CR29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.16078","volume":"178","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178:925\u201330.","journal-title":"Br J Dermatol"},{"key":"1312_CR30","first-page":"8","volume":"2","author":"L Stingeni","year":"2024","unstructured":"Stingeni L, Napolitano M, Hansel K, Foti C, Corazza M, Borghi A, et al. Hand eczema in Italian patients referred for patch testing: a retrospective SIDAPA study (2016\u20132023). Contact Dermatitis. 2024;2:8.","journal-title":"Contact Dermatitis"},{"key":"1312_CR31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.12819","volume":"171","author":"RF Ofenloch","year":"2014","unstructured":"Ofenloch RF, Weisshaar E, Dumke A-K, Molin S, Diepgen TL, Apfelbacher C. The quality of life in hand eczema questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171:304\u201312.","journal-title":"Br J Dermatol"},{"key":"1312_CR32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/DER.0000000000000054","volume":"25","author":"C Patruno","year":"2014","unstructured":"Patruno C, Ayala F, Zagaria O, Balato N. Is cigarette smoking dangerous for chronic hand eczema in housewives? Dermatitis. 2014;25:201\u20134.","journal-title":"Dermatitis"},{"key":"1312_CR33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cod.13278","volume":"81","author":"L Stingeni","year":"2019","unstructured":"Stingeni L, Tramontana M, Bianchi L, Foti C, Patruno C, Gallo R, et al. Contact sensitivity to 2-hydroxyethyl methacrylate in consecutive patients: a 1-year multicentre SIDAPA study. Contact Dermatitis. 2019;81:216\u20138.","journal-title":"Contact Dermatitis"},{"key":"1312_CR34","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1111\/jdv.17429","volume":"35","author":"M Tramontana","year":"2021","unstructured":"Tramontana M, Hansel K, Bianchi L, Marietti R, Stingeni L. Use of self-applied sculptured gel nails may increase the risk of allergy to (meth)acrylates in children and adolescents. J Eur Acad Dermatol Venereol. 2021;35:e765\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1312_CR35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/12034754231188325","volume":"27","author":"JSS Ho","year":"2023","unstructured":"Ho JSS, Molin S. A review of existing and new treatments for the management of hand eczema. J Cutan Med Surg. 2023;27:493\u2013503.","journal-title":"J Cutan Med Surg"},{"key":"1312_CR36","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","volume":"35","author":"J Silverberg","year":"2021","unstructured":"Silverberg J, Thyssen J, Fahrbach K, Mickle K, Cappelleri J, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35:1797\u2013810.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1312_CR37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12:445\u201359.","journal-title":"Patient"},{"key":"1312_CR38","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJMcp1104084","volume":"367","author":"P-J Coenraads","year":"2012","unstructured":"Coenraads P-J. Hand eczema. N Engl J Med. 2012;367:1829\u201337.","journal-title":"N Engl J Med"},{"key":"1312_CR39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4103\/2229-5178.330844","volume":"12","author":"R Varma","year":"2021","unstructured":"Varma R, Devi K, Asokan N. A cross-sectional analysis on hand eczema: severity and quality of life. Indian Dermatol Online J. 2021;12:952\u20133.","journal-title":"Indian Dermatol Online J"},{"key":"1312_CR40","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jdv.19055","volume":"37","author":"H R\u00f6nsch","year":"2023","unstructured":"R\u00f6nsch H, Schiffers F, Ofenloch R, Weisshaar E, Buse AS, Hansen A, et al. Chronic hand eczema in Europe: Patient experiences and perspectives ( CHEPEP ) in qualitative interviews. Acad Dermatol Venereol. 2023;37:1396\u2013405.","journal-title":"Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"1312_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jdv.16062","volume":"34","author":"P Elsner","year":"2020","unstructured":"Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):13\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1312_CR42","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2022.2087059","volume":"31","author":"J Cheng","year":"2022","unstructured":"Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. Expert Opin Investig Drugs. 2022;31:843\u201353.","journal-title":"Expert Opin Investig Drugs"},{"key":"1312_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"1312_CR44","first-page":"1629","volume":"8","author":"T King","year":"2014","unstructured":"King T, McKenna J, Alexandroff AB. Alitretinoin for the treatment of severe chronic hand eczema. Patient Prefer Adherence. 2014;8:1629\u201334.","journal-title":"Patient Prefer Adherence"},{"key":"1312_CR45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/25785826.2019.1642727","volume":"42","author":"H Suga","year":"2019","unstructured":"Suga H, Sato S. Novel topical and systemic therapies in atopic dermatitis. Immunol Med. 2019;42:84\u201393.","journal-title":"Immunol Med"},{"key":"1312_CR46","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjd.18295","volume":"182","author":"JAF Oosterhaven","year":"2020","unstructured":"Oosterhaven JAF, Schuttelaar MLA. Responsiveness and interpretability of the hand eczema severity index. Br J Dermatol. 2020;182:932\u20139.","journal-title":"Br J Dermatol"},{"key":"1312_CR47","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1080\/09546634.2021.1967267","volume":"33","author":"A Patrizi","year":"2022","unstructured":"Patrizi A, Costanzo A, Patruno C, Bus\u00e0 VM, Chiricozzi A, Girolomoni G. Unmet needs in atopic dermatitis management: an expert consensus. J Dermatolog Treat. 2022;33:2459\u201365.","journal-title":"J Dermatolog Treat"},{"key":"1312_CR48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3349\/ymj.2019.60.7.694","volume":"60","author":"MK Lee","year":"2019","unstructured":"Lee MK, Seo J-H, Chu H, Kim H, Jang YH, Jeong JW, et al. Current status of patient education in the management of atopic dermatitis in Korea. Yonsei Med J. 2019;60:694\u20139.","journal-title":"Yonsei Med J"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01312-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01312-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:30:40Z","timestamp":1738380640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01312-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01312-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors disclose the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Luca Stingeni has acted as Principal Investigator, speaker, and board member for AbbVie, Almirall, Amgen, Bristol Meyer Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis and Sanofi. Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and\/or research grants from Amgen, Almirall, AbbVie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron and Sun Pharma. Fabrizio Guarneri has served as advisory board member for Leo Pharma. Anna Balato has served as advisory board member, consultant and\/or has received fees, speakers\u2019 honoraria or has participated in clinical trials for AbbVie, Almirall, Amgen, Boehringer-Ingelheim, BMS, LeoPharma, Eli Lilly, Incyte, Janssen, Novartis, Sanofi and UCB. Monica Corazza has acted as Principal Investigator, speaker, and board member for AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Novartis and Sanofi. Anna Belloni Fortina has participated in advisory boards, acted as consultant and\/or received fees from AbbVie, Amgen, Almirall, Sanofi Genzyme, Leo Pharma, Eli Lilly, Pfizer, Unifarco and Novartis. Piergiacomo Calzavara-Pinton served as advisory board member and consultant and has received fees and speakers\u2019 honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Cantabria, Galderma, Incyte, Janssen, Novartis, Biogen, Sanofi Genzyme, La Roche Posay, Naos, Boehringer-Ingelheim and Sun Pharma. Antonio Castanzo has served as advisory board member and consultant and has received fees and speakers\u2019 honoraria or has participated in clinical trials for AbbVie, Almirall, Amgen Leo Pharma, Lilly, Galderma, Incyte, Janssen, Novartis, Sanofi Genzyme, Boehringer-Ingelheim and UCB. Silvia Mariel Ferrucci has acted as Principal Investigator in clinical trials, Speaker and Member of Advisory board for: AbbVie, Amgen, Almirall, Bayer, Sanofi Genzyme, Leo Pharma, Eli Lilly, Pfizer, Unifarco and Novartis. Luigi Naldi has been consultant and speaker for AbbVie, Almirall, Boheringer Ingelheim, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis and Sanofi. Giovanni Pellacani has served as advisory board member, consultant and investigator for: AbbVie, Allergan, Almirall, Amgen, Beiersdorf, Boheringer, Canfield, Difa-Cooper Ifc, Eli Lilly, Galderma, Janssen-Cilag, Krymi, Kyowa-Kirin, Leo Pharma, L\u2019oreal, Mavig, Menarini, Pfizer, Pierre-Fabre, Sanofi, UCB and Viatris. Ketty Peris received grants from: AbbVie, Almirall, Lilly, Novartis and Sanofi; Advisory Board or consulting fees from: AbbVie, Almirall, Biogen, Galderma, Leo Pharma, Lilly, MSD, Pierre Fabre, Sun Pharma, Janssen and Sanofi. Francesca Prignano has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Lilly, Janssen, Novartis, Biogen, Sanofi Genzyme, UCB and Boehringer-Ingelheim. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim,\u00a0Bristol-Myers Squibb, Eli Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on data derived from a survey conducted among dermatologists and previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}